U.S. Markets closed

MorphoSys AG (MOR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.15-0.17 (-1.38%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.32
Open12.50
Bid9.00 x 1100
Ask13.75 x 3200
Day's Range12.15 - 12.53
52 Week Range11.76 - 31.97
Volume52,697
Avg. Volume80,130
Market Cap1.626B
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-1.27
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.45
  • Zacks

    Incyte (INCY) Jakafi Wins FDA Approval for Chronic GVHD

    Incyte's (INCY) going gets good with another FDA approval - Jakafi for the treatment of chronic GVHD. However, the stock witnesses a decline despite the recent approvals.

  • Zacks

    Incyte (INCY) Ruxolitinib Cream Wins FDA Nod for Atopic Dermatitis

    Incyte (INCY) obtains FDA approval for the cream formulation of ruxolitinib for the treatment of mild to moderate atopic dermatitis.

  • Benzinga

    Incyte - MorphoSys's Diffuse Large B-Cell Lymphoma Drug Wins European Approval

    The European Commission (EC) has granted conditional approval to Incyte Corporation (NASDAQ: INCY) - MorphoSys AG's (NASDAQ: MOR) Minjuvi (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval covers Minjuvi combined with lenalidomide, followed by Minjuvi monotherapy, for DLBCL patients who are not eligible for autologous stem cell transplant (ASCT). The conditional approval is based on the results from the L-MIND study that showed the best objective respons